Methylprednisolone hemisuccinate

Generic Name: Methylprednisolone hemisuccinate

Brand Names: Solu-medrol

Drug Type: Small Molecule

Chemical Formula: C_₂₆H_₃₄O_₈

CAS Number: 2921-57-5

Unique Ingredient Identifier: 5GMR90S4KN

Background: A water-soluble ester of methylprednisolone used for cardiac, allergic, and hypoxic emergencies.

Associated Conditions: Acute Gouty Arthritis, Ankylosing Spondylitis (AS), Berylliosis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Dermatitis bullous, Dermatomyositis (DM), Edema of the cerebrum, Hypercalcemia of Malignancy, Immune Thrombocytopenia (ITP), Leukemias, Lymphoma, Multiple sclerosis exacerbation, Mycosis Fungoides (MF), Ophthalmia, Sympathetic, Pemphigus, Polymyositis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Refractory Uveitis, Regional Enteritis, Rheumatoid Arthritis, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Temporal Arteritis, Trichinosis, Tuberculous Meningitis, Ulcerative Colitis, Acquired immune hemolytic anemia, Acute rheumatic carditis, Disseminated Pulmonary Tuberculosis (TB), Exfoliative erythroderma, Fulminating Pulmonary Tuberculosis, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Allergic Reactions, Symptomatic Sarcoidosis

Associated Therapies: Palliative Treatment

Clinical Trials

Busulfan, Melphalan, and Antithymocyte Globulin Followed By Umbilical Cord Blood Transplant in Treating Young Patients With Refractory or Relapsed Malignant Solid Tumors

Phase 1

Conditions: Unspecified Childhood Solid Tumor, Protocol Specific

First Posted Date: 2007-02-19

Last Posted Date: 2013-12-18

Lead Sponsor: Milton S. Hershey Medical Center

Target Recruit Count: 20

Registration Number: NCT00436761

Locations: 🇺🇸
Penn State Cancer Institute at Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States

Steroids In caRdiac Surgery Trial (SIRS Trial)

Phase 4

Conditions: Systemic Inflammatory Response Syndrome
Cardiac Surgical Procedures
Cardiopulmonary Bypass

Interventions: Drug: Methylprednisolone
Other: Placebo

First Posted Date: 2007-01-29

Last Posted Date: 2014-08-04

Lead Sponsor: Population Health Research Institute

Target Recruit Count: 7507

Registration Number: NCT00427388

Locations: 🇨🇦
Hamilton General Hospital, Hamilton, Ontario, Canada

Hematopoietic Stem Cell Therapy for Patients With Refractory Myasthenia Gravis

Phase 1

Terminated

Conditions: Myasthenia Gravis

Interventions: Biological: Hematopoietic Stem Cell Transplantation
Drug: Cyclophosphamide
Drug: ATG (rabbit)
Drug: Mesna
Drug: Methylprednisolone
Drug: G-CSF

First Posted Date: 2007-01-19

Last Posted Date: 2018-08-31

Lead Sponsor: Northwestern University

Target Recruit Count: 9

Registration Number: NCT00424489

Locations: 🇺🇸
Northwestern University, Feinberg School of Medicine, Chicago, Illinois, United States

Efficacy and Safety of Enteric-coated Mycophenolate Sodium in Combination With Two Corticosteroid Regimens for the Treatment of Lupus Nephritis Flare

Phase 2

Completed

Conditions: Lupus Nephritis

Interventions: Drug: Mycophenolate sodium
Drug: Prednisone
Drug: Methylprednisolone

First Posted Date: 2007-01-17

Last Posted Date: 2011-06-28

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 81

Registration Number: NCT00423098

Locations: 🇬🇧
Novartis, Cambridge, United Kingdom
🇫🇷
Novartis Investigative Site, Paris, France

Alemtuzumab and Glucocorticoids in Treating Newly Diagnosed Acute Graft-Versus-Host Disease in Patients Who Have Undergone a Donor Stem Cell Transplant

Phase 2

Completed

Conditions: Breast Cancer
Chronic Myeloproliferative Disorders
Gestational Trophoblastic Tumor
Graft Versus Host Disease
Leukemia
Lymphoma
Multiple Myeloma and Plasma Cell Neoplasm
Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Diseases
Neuroblastoma

First Posted Date: 2006-12-13

Last Posted Date: 2010-05-14

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 53

Registration Number: NCT00410657

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Treatment of Acute Lymphoblastic Leukemia in Children

Phase 3

Completed

Conditions: Drug/Agent Toxicity by Tissue/Organ
Leukemia

Interventions: Drug: asparaginase
Drug: cyclophosphamide
Drug: cytarabine
Drug: dexamethasone
Drug: dexrazoxane hydrochloride
Drug: doxorubicin hydrochloride
Drug: leucovorin calcium
Drug: etoposide
Drug: mercaptopurine
Drug: methotrexate
Drug: methylprednisolone
Drug: pegaspargase
Drug: prednisolone
Drug: therapeutic hydrocortisone
Drug: vincristine sulfate
Radiation: radiation therapy

First Posted Date: 2006-11-17

Last Posted Date: 2024-11-27

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 800

Registration Number: NCT00400946

Locations: 🇨🇦
McMaster Children's Hospital at Hamilton Health Sciences, Hamilton, Ontario, Canada
🇺🇸
Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, New York, New York, United States
🇨🇦
Centre de Recherche du Centre Hospitalier de l'Universite Laval, Sainte Foy, Quebec, Canada

and more 5 locations

A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus

Phase 3

Terminated

Conditions: Lupus Erythematosus, Systemic

Interventions: Drug: Rituximab
Drug: Methylprednisolone
Drug: Acetaminophen
Drug: Diphenhydramine

First Posted Date: 2006-09-28

Last Posted Date: 2017-08-01

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 31

Registration Number: NCT00381810

Locations: 🇺🇸
Arizona Arthritis & Rheumatology Research, Pllc, Paradise Valley, Arizona, United States
🇺🇸
Eden Medical Center San Leandro Hospital, San Leandro, California, United States
🇺🇸
Intermountain Research Center, Boise, Idaho, United States

and more 8 locations

Laboratory-Treated Lymphocyte Infusion After Haploidentical Donor Stem Cell Transplant

Phase 1

Completed

Conditions: Leukemia
Myelodysplastic Syndromes

Interventions: Biological: anti-thymocyte globulin
Biological: peripheral blood lymphocyte therapy
Drug: fludarabine phosphate
Drug: methylprednisolone
Drug: thiotepa
Procedure: allogeneic hematopoietic stem cell transplantation
Procedure: in vitro-treated peripheral blood stem cell transplantation
Radiation: total-body irradiation

First Posted Date: 2006-09-15

Last Posted Date: 2019-07-05

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 19

Registration Number: NCT00376480

Locations: 🇺🇸
M. D. Anderson Cancer Center at University of Texas, Houston, Texas, United States
🇺🇸
University of Florida Health Science Center - Gainesville, Gainesville, Florida, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

and more 3 locations